Philip Clarke
Philip Clarke
Professor of health economics, university of melbourne
Verified email at
Cited by
Cited by
Applied methods of cost-effectiveness analysis in healthcare
AM Gray, PM Clarke, JL Wolstenholme, S Wordsworth
OUP Oxford, 2010
A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)
PM Clarke, AM Gray, A Briggs, AJ Farmer, P Fenn, RJ Stevens, ...
Diabetologia 47 (10), 1747-1759, 2004
Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62)
P Clarke, A Gray, R Holman
Medical Decision Making 22 (4), 340-349, 2002
Missing.... presumed at random: cost‐analysis of incomplete data
A Briggs, T Clark, J Wolstenholme, P Clarke
Health economics 12 (5), 377-392, 2003
UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom …
AJ Hayes, J Leal, AM Gray, RR Holman, PM Clarke
Diabetologia 56 (9), 1925-1933, 2013
The impact of diabetes‐related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65)
P Clarke, A Gray, R Legood, A Briggs, R Holman
Diabetic Medicine 20 (6), 442-450, 2003
Estimating the association between SF-12 responses and EQ-5D utility values by response mapping
AM Gray, O Rivero-Arias, PM Clarke
Medical Decision Making 26 (1), 18-29, 2006
Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial
J Simon, A Gray, P Clarke, A Wade, A Neil, A Farmer
bmj 336 (7654), 1177-1180, 2008
Applied methods of cost-benefit analysis in health care
E McIntosh, P Clarke, E Frew, J Louviere
Oxford University Press, 2010
Effects of allopurinol on the progression of chronic kidney disease
SV Badve, EM Pascoe, A Tiku, N Boudville, FG Brown, A Cass, P Clarke, ...
New England Journal of Medicine 382 (26), 2504-2513, 2020
Optimal recall length in survey design
PM Clarke, DG Fiebig, UG Gerdtham
Journal of health economics 27 (5), 1275-1284, 2008
On the measurement of relative and absolute income-related health inequality
PM Clarke, UG Gerdtham, M Johannesson, K Bingefors, L Smith
Social science & medicine 55 (11), 1923-1928, 2002
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
JCN Chan, LL Lim, NJ Wareham, JE Shaw, TJ Orchard, P Zhang, ...
The Lancet 396 (10267), 2019-2082, 2020
Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)
PM Clarke, AM Gray, A Briggs, RJ Stevens, DR Matthews, RR Holman
Diabetologia 48 (5), 868-877, 2005
Development of life-expectancy tables for people with type 2 diabetes
J Leal, AM Gray, PM Clarke
European heart journal 30 (7), 834-839, 2009
Forgetting to remember or remembering to forget: a study of the recall period length in health care survey questions
G Kjellsson, P Clarke, UG Gerdtham
Journal of health economics 35, 34-46, 2014
Horizontal inequities in Australia's mixed public/private health care system
E Van Doorslaer, P Clarke, E Savage, J Hall
Health Policy 86 (1), 97-108, 2008
Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis
PM Clarke, P Glasziou, A Patel, J Chalmers, M Woodward, SB Harrap, ...
PLoS medicine 7 (2), e1000236, 2010
Survival of the fittest: retrospective cohort study of the longevity of Olympic medallists in the modern era
PM Clarke, SJ Walter, A Hayen, WJ Mallon, J Heijmans, DM Studdert
Bmj 345, 2012
Expenditures and prices of antihyperglycemic medications in the United States: 2002-2013
X Hua, N Carvalho, M Tew, ES Huang, WH Herman, P Clarke
Jama 315 (13), 1400-1402, 2016
The system can't perform the operation now. Try again later.
Articles 1–20